RecruitingPhase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Hungary, Spain8 participantsStarted 2025-03-24

Plain-language summary

The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Participants must have an advanced, unresectable, or metastatic solid tumor malignancy with a deletion of the methylthioadenosine phosphorylase (MTAP) gene. * Participants must have received, be refractory to, be ineligible for, or be intolerant of available standard care for their cancer. Exclusion Criteria * Participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body. * Participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center. * Participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease. * Other protocol-defined Inclusion/Exclusion criteria apply.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Maximum observed concentration (Cmax)

Timeframe: Up to 2 weeks

Time of maximum observed drug concentration (Tmax)

Timeframe: Up to 2 weeks

Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

Timeframe: Up to 2 weeks

Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

Timeframe: Up to 2 weeks

Terminal elimination half-life (T-HALF)

Timeframe: Up to 2 weeks

Apparent total body clearance (CLT/F)

Timeframe: Up to 2 weeks

Apparent volume of distribution during the terminal phase (Vz/F)

Timeframe: Up to 2 weeks

Trial details

NCT IDNCT06672523

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-10-25

Contact for this trial

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 Clinical.Trials@bms.com

View on ClinicalTrials.gov More Advanced Solid Tumors With Homozygous MTAP Deletion trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Maximum observed concentration (Cmax)

Timeframe: Up to 2 weeks

Time of maximum observed drug concentration (Tmax)

Timeframe: Up to 2 weeks

Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

Timeframe: Up to 2 weeks

Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

Timeframe: Up to 2 weeks

Terminal elimination half-life (T-HALF)

Timeframe: Up to 2 weeks

Apparent total body clearance (CLT/F)

Timeframe: Up to 2 weeks

Apparent volume of distribution during the terminal phase (Vz/F)

Timeframe: Up to 2 weeks